Sam Brusco, Associate Editor10.18.23
MiRus has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its CYGNUS MoRe anterior cervical plate and MiRus 3DR lateral lumbar interbody fusion (LLIF) system with integrated MoRe plate fixation.
The company claims both are the narrowest and thinnest plating systems among all plates on the market.
The proprietary molybdenum-rhenium alloy used in the MoRe lateral plate allows for a smaller footprint of tapered 2 mm thickness, without sacrificing performance. In a lateral spinal fusion approach, there’s little room or empty space around the critical structures of the nerves and psoas, and the company believes there is significant clinical benefit from a plate that is 40-60% thinner than those currently on the market.
“The CYGNUS MoRe Anterior Cervical Plate is a world class product in the ACDF marketplace that furthers our commitment to minimally invasive, stronger biofriendly implants," MiRus chief commercial officer Mahesh Krishnan told the press. "With its thin 1.0mm profile, the CYGNUS MoRe ACP will lead to less retraction and anterior vertebral body preparation resulting in shorter operative times and minimizing risk of complications such as dysphagia and dysphonia in patients undergoing anterior cervical fusion."
"Both the CYGNUS MoRe ACP and the MiRus 3DR Lateral Lumbar Interbody Fusion system with Integrated MoRe plate fixation are major accomplishments in the global spine market, as we strive to develop products that are best in class with a resolve to provide meaningful innovations to surgeons that improve patient outcomes," added Jay Yadav, MD, founder and CEO of MiRus.
The company claims both are the narrowest and thinnest plating systems among all plates on the market.
The proprietary molybdenum-rhenium alloy used in the MoRe lateral plate allows for a smaller footprint of tapered 2 mm thickness, without sacrificing performance. In a lateral spinal fusion approach, there’s little room or empty space around the critical structures of the nerves and psoas, and the company believes there is significant clinical benefit from a plate that is 40-60% thinner than those currently on the market.
“The CYGNUS MoRe Anterior Cervical Plate is a world class product in the ACDF marketplace that furthers our commitment to minimally invasive, stronger biofriendly implants," MiRus chief commercial officer Mahesh Krishnan told the press. "With its thin 1.0mm profile, the CYGNUS MoRe ACP will lead to less retraction and anterior vertebral body preparation resulting in shorter operative times and minimizing risk of complications such as dysphagia and dysphonia in patients undergoing anterior cervical fusion."
"Both the CYGNUS MoRe ACP and the MiRus 3DR Lateral Lumbar Interbody Fusion system with Integrated MoRe plate fixation are major accomplishments in the global spine market, as we strive to develop products that are best in class with a resolve to provide meaningful innovations to surgeons that improve patient outcomes," added Jay Yadav, MD, founder and CEO of MiRus.